Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.
Sabrina Rebello, Amyloidosis Research Consortium, Newton, MA

Main Body of the Abstract
Introduction Leukocyte Chemotactic Factor 2 (ALECT2) amyloidosis is the third most common renal amyloidosis and the second most common hepatic amyloidosis. ALECT2 amyloidosis is more prevalent among individuals of Hispanic, Native American, and Middle Eastern ancestry. Currently, no effective treatments are available for ALECT2 amyloidosis. This analysis examined the demographic and clinical characteristics of patients with ALECT2 amyloidosis participating in a multi-country survey study.

Methods The Amyloidosis Research Consortium conducted an online cross-sectional survey of amyloidosis patients in the US, Germany, New Zealand, France, Italy, Spain, and Portugal in September 2023. Survey measures included demographic and clinical characteristics, including symptom severity.

Results Of the 1031 survey respondents, 24 (2.3%) had ALECT2 amyloidosis and were included in this analysis. Two-thirds of patients (n=16) were of Hispanic/Latino ancestry, 13 (54%) were female, and mean (Standard Deviation [SD]) age was 66 (7) years (Table). The mean (SD) time since diagnosis was 5 (4) years. The majority (96%) reported kidney involvement and 2 (8%) had liver involvement. One-third (n=8) reported their current symptom severity as absent/mild, 11 (46%) had moderate symptoms, and 5 (21%) reported severe/very severe symptoms.

Conclusions The demographics of surveyed patients with ALECT2 amyloidosis are described, and two-thirds of patients may experience moderate/severe symptoms. Further studies are needed to understand more about this patient population and address the unmet needs of ALECT2 amyloidosis patients.

**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Sabrina Rebello, Amyloidosis Research Consortium, Newton, MA

**Main Body of the Abstract**
**Introduction** Leukocyte Chemotactic Factor 2 (ALECT2) amyloidosis is the third most common renal amyloidosis and the second most common hepatic amyloidosis. ALECT2 amyloidosis is more prevalent among individuals of Hispanic, Native American, and Middle Eastern ancestry. Currently, no effective treatments are available for ALECT2 amyloidosis. This analysis examined the demographic and clinical characteristics of patients with ALECT2 amyloidosis participating in a multi-country survey study.

**Methods** The Amyloidosis Research Consortium conducted an online cross-sectional survey of amyloidosis patients in the US, Germany, New Zealand, France, Italy, Spain, and Portugal in September 2023. Survey measures included demographic and clinical characteristics, including symptom severity.

**Results** Of the 1031 survey respondents, 24 (2.3%) had ALECT2 amyloidosis and were included in this analysis. Two-thirds of patients (n=16) were of Hispanic/Latino ancestry, 13 (54%) were female, and mean (Standard Deviation [SD]) age was 66 (7) years (Table). The mean (SD) time since diagnosis was 5 (4) years. The majority (96%) reported kidney involvement and 2 (8%) had liver involvement. One-third (n=8) reported their current symptom severity as absent/mild, 11 (46%) had moderate symptoms, and 5 (21%) reported severe/very severe symptoms.

**Conclusions** The demographics of surveyed patients with ALECT2 amyloidosis are described, and two-thirds of patients may experience moderate/severe symptoms. Further studies are needed to understand more about this patient population and address the unmet needs of ALECT2 amyloidosis patients.

Characteristics of Leukocyte Chemotactic Factor 2 (ALect2) Amyloidosis Patients from the Amyloidosis Research Consortium’s 2023 Multi-Country Amyloidosis Community Survey PC86 (#320)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.